ClinVar Miner

Submissions for variant NM_002473.6(MYH9):c.4400C>T (p.Ala1467Val)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Molecular Genetics, Royal Melbourne Hospital RCV003994670 SCV004812560 uncertain significance Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss 2023-03-30 criteria provided, single submitter clinical testing This sequence change in MYH9 is predicted to replace alanine with valine at codon 1467, p.(Ala1467Val). The alanine residue is highly conserved (100 vertebrates, UCSC), and is located in the myosin tail 1 domain. There is a moderate physicochemical difference between alanine and valine. The highest population minor allele frequency in gnomAD v2.1 is 0.002% (2/113,160 alleles) in the European (non-Finnish) population, which is lower than the credible allele frequency for dominant hearing loss genes (MYH9 included). To our knowledge, this variant has not been reported in the literature in any individuals with MYH9-related disease. Multiple lines of computational evidence have conflicting predictions for the missense substitution (4/6 algorithms predict deleterious). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PM2_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.